{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:09:10Z","timestamp":1788390550453,"version":"build-2803163510"},"reference-count":94,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The human immunodeficiency virus (HIV) infection continues to be a social and public health problem. Thanks to more and more effective antiretroviral therapy (ART), nowadays HIV-positive patients live longer, thus increasing their probability to acquire other diseases, malignancies primarily. Senescence along with immune-system impairment, HIV-related habits and other oncogenic virus co-infections increase the cancer risk of people living with HIV (PLWH); in the next future non-AIDS-defining cancers will prevail, lung cancer (LC) in particular. Tumor in PLWH might own peculiar predictive and\/or prognostic features, and antineoplastic agents\u2019 activity might be subverted by drug-drug interactions (DDIs) due to concurrent ART. Moreover, PLWH immune properties and comorbidities might influence both the response and tolerability of oncologic treatments. The therapeutic algorithm of LC, rapidly and continuously changed in the last years, should be fitted in the context of a special patient population like PLWH. This is quite challenging, also because HIV-positive patients have been often excluded from participation to clinical trials, so that levels of evidence about systemic treatments are lower than evidence in HIV-uninfected individuals. With this review, we depicted the epidemiology, pathogenesis, clinical-pathological characteristics and implications for LC care in PLWH, offering a valid focus about this topic to clinicians.<\/jats:p>","DOI":"10.3390\/ijms21051601","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T03:21:16Z","timestamp":1582773676000},"page":"1601","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment"],"prefix":"10.3390","volume":"21","author":[{"given":"Stefano","family":"Frega","sequence":"first","affiliation":[{"name":"Medical Oncology 2, Istituto Oncologico Veneto IOV- IRCCS, 35, 128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferro","sequence":"additional","affiliation":[{"name":"Medical Oncology 2, Istituto Oncologico Veneto IOV- IRCCS, 35, 128 Padova, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova, 35, 128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4810-7136","authenticated-orcid":false,"given":"Laura","family":"Bonanno","sequence":"additional","affiliation":[{"name":"Medical Oncology 2, Istituto Oncologico Veneto IOV- IRCCS, 35, 128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[{"name":"Medical Oncology 2, Istituto Oncologico Veneto IOV- IRCCS, 35, 128 Padova, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova, 35, 128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PierFranco","family":"Conte","sequence":"additional","affiliation":[{"name":"Medical Oncology 2, Istituto Oncologico Veneto IOV- IRCCS, 35, 128 Padova, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova, 35, 128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[{"name":"Medical Oncology 2, Istituto Oncologico Veneto IOV- IRCCS, 35, 128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"ref_1","unstructured":"(2019, October 10). Global HIV & AIDS Statistics\u20142019 Fact Sheet|UNAIDS. Available online: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2138259","DOI":"10.1155\/2016\/2138259","article-title":"Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy","volume":"2016","author":"Lee","year":"2016","journal-title":"J. Cancer Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: A meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"ref_4","unstructured":"(2019, July 14). Impact of the Expanded AIDS Surveillance Case Definition on AIDS Case Reporting\u2014United States, First Quarter, 1993, Available online: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/00020374.htm."},{"key":"ref_5","first-page":"CD008272","article-title":"Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults","volume":"17","author":"Siegfried","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/QAD.0000000000000071","article-title":"Malignancies in HIV\/AIDS: From epidemiology to therapeutic challenges","volume":"28","author":"Rubinstein","year":"2014","journal-title":"AIDS"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.2011.396","article-title":"Proportions of Kaposi Sarcoma, Selected Non-Hodgkin Lymphomas, and Cervical Cancer in the United States Occurring in Persons With AIDS, 1980-2007","volume":"305","author":"Shiels","year":"2011","journal-title":"JAMA"},{"key":"ref_8","first-page":"1032","article-title":"Evolving epidemiology of HIV-associated malignancies","volume":"25","author":"Meredith","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-Associated Cancers and Related Diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-981-10-5765-6_10","article-title":"Malignancies in HIV-Infected and AIDS patients","volume":"1018","author":"Ji","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"866","DOI":"10.7326\/M17-2499","article-title":"Projected Cancer Incidence Rates and Burden of Incident Cancer Cases in HIV-Infected Adults in the United States Through 2030","volume":"168","author":"Shiels","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/COH.0000000000000326","article-title":"Lung cancer in persons with HIV","volume":"12","author":"Sigel","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/QAI.0b013e3181b327ca","article-title":"A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals","volume":"52","author":"Shiels","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/bjc.2012.181","article-title":"Comment on \u2018Lung cancer in the Swiss HIV Cohort Study: Role of smoking, immunodeficiency and pulmonary infection\u2019","volume":"106","author":"Bearz","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M14-0954","article-title":"Cigarette Smoking Prevalence Among Adults With HIV Compared With the General Adult Population in the United States","volume":"162","author":"Mdodo","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/QAD.0b013e328352d1ad","article-title":"HIV as an independent risk factor for incident lung cancer","volume":"26","author":"Sigel","year":"2012","journal-title":"AIDS"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1183\/13993003.00353-2015","article-title":"Impact of HIV infection and smoking on lung immunity and related disorders","volume":"46","author":"Rossouw","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.2005.03.4413","article-title":"Elevated Incidence of Lung Cancer Among HIV-Infected Individuals","volume":"24","author":"Engels","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijid.2018.10.011","article-title":"Non-AIDS-related comorbidities in people living with HIV-1 aged 50 years and older: The AGING POSITIVE study","volume":"79","author":"Velez","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1086\/518606","article-title":"HIV Infection Is Associated with an Increased Risk for Lung Cancer, Independent of Smoking","volume":"45","author":"Kirk","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/QAD.0000000000000540","article-title":"Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America","volume":"29","author":"Helleberg","year":"2015","journal-title":"AIDS"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccm.2013.01.008","article-title":"Human Immunodeficiency Virus\u2013Associated Lung Malignancies","volume":"34","author":"Lambert","year":"2013","journal-title":"Clin. Chest Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1378\/chest.12-1699","article-title":"Epidemic of Lung Cancer in Patients With HIV Infection","volume":"143","author":"Winstone","year":"2013","journal-title":"Chest"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/cid\/ciu869","article-title":"Comparison of Risk and Age at Diagnosis of Myocardial Infarction, End-Stage Renal Disease, and Non-AIDS-Defining Cancer in HIV-Infected Versus Uninfected Adults","volume":"60","author":"Althoff","year":"2015","journal-title":"Clin. Infect Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/cncr.21334","article-title":"Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals","volume":"104","author":"Burgi","year":"2005","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2008.19.6626","article-title":"Highly Active Antiretroviral Therapy and the Incidence of Non\u2013AIDS-Defining Cancers in People With HIV Infection","volume":"27","author":"Powles","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/QAD.0b013e32834e8805","article-title":"Long-term exposure to combination antiretroviral therapy and risk of death from specific causes","volume":"26","author":"Kowalska","year":"2012","journal-title":"AIDS"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cllc.2011.05.005","article-title":"Lung Cancer in HIV Infection","volume":"13","author":"Mani","year":"2012","journal-title":"Clin. Lung Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1378\/chest.102.6.1704","article-title":"Lung Cancer in Patients with Human Immunodeficiency Virus Infection Compared with Historic Control Subjects","volume":"102","author":"Sridhar","year":"2019","journal-title":"Chest"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<563::AID-CNCR11>3.0.CO;2-D","article-title":"Lung carcinoma in 36 patients with human immunodeficiency virus infection","volume":"88","author":"Tirelli","year":"2000","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.qai.0000232260.95288.93","article-title":"Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: Implications for patient care","volume":"43","author":"Brock","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1055-9965.EPI-14-1079","article-title":"Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers","volume":"24","author":"Marcus","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000458442","article-title":"HIV-associated lung cancer","volume":"40","author":"Kiderlen","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/bjc.2017.333","article-title":"Clinically significant mutations in HIV-infected patients with lung adenocarcinoma","volume":"117","author":"Thaler","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_35","first-page":"1","article-title":"HIV-associated Non-small-cell Lung Cancer with Rearrangement of the Anaplastic Lymphoma Kinase Gene: A Report of Two Patients","volume":"11","author":"Pichardo","year":"2019","journal-title":"Cureus"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13128","DOI":"10.1038\/s41598-018-31572-6","article-title":"Molecular Changes of Lung Malignancy in HIV Infection","volume":"8","author":"Zheng","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1172\/JCI37815","article-title":"The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling","volume":"119","author":"Micalizzi","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fonc.2014.00323","article-title":"Prom1 function in development, intestinal inflammation, and intestinal tumorigenesis","volume":"4","author":"Karim","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/15384101.2018.1557487","article-title":"HIV-1 Nef promotes cell proliferation and microRNA dysregulation in lung cells","volume":"18","author":"Santerre","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/bjc.2013.545","article-title":"Prognosis in HIV-infected patients with non-small cell lung cancer","volume":"109","author":"Sigel","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/QAI.0b013e3181f53783","article-title":"Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users","volume":"55","author":"Shiels","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e0361","DOI":"10.1097\/MD.0000000000010361","article-title":"Human immunodeficiency virus infection and mortality risk among lung cancer patients","volume":"97","author":"Wang","year":"2018","journal-title":"Medcine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/cncr.30052","article-title":"Disparities in cancer treatment among patients infected with the human immunodeficiency virus","volume":"122","author":"Suneja","year":"2016","journal-title":"Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.athoracsur.2011.11.012","article-title":"Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer","volume":"93","author":"Hooker","year":"2012","journal-title":"Ann. Thorac. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archsurg.141.12.1238","article-title":"Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy","volume":"141","author":"Horberg","year":"2006","journal-title":"Arch. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1097\/QAD.0000000000002200","article-title":"Short-term outcomes for lung cancer resection surgery in HIV infection","volume":"33","author":"Sigel","year":"2019","journal-title":"AIDS"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11748-019-01149-9","article-title":"Clinical features of HIV-infected patients with non-small-cell lung cancer after lung resection","volume":"68","author":"Asakawa","year":"2019","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S1470-2045(17)30440-0","article-title":"Radiotherapy in patients with HIV: Current issues and review of the literature","volume":"18","author":"Alongi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Coghill, A.E., Suneja, G., Rositch, A.F., Shiels, M.S., and Engels, E.A. (2019). HIV Infection, Cancer Treatment Regimens, and Cancer Outcomes Among Elderly Adults in the United States. JAMA Oncol.","DOI":"10.1001\/jamaoncol.2019.1742"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.critrevonc.2008.10.013","article-title":"Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice","volume":"72","author":"Mounier","year":"2009","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/cid\/ciu174","article-title":"Management of HIV infection in patients with cancer receiving chemotherapy","volume":"59","author":"Torres","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.biopha.2014.04.010","article-title":"Drug-drug interactions in HIV positive cancer patients","volume":"68","author":"Flepisi","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/clpt.2014.10","article-title":"Pharmacotherapy in cancer patients with HIV\/AIDS","volume":"95","author":"Beumer","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fphar.2016.00071","article-title":"Drug-drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection","volume":"7","author":"Berretta","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00280-014-2399-7","article-title":"Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure","volume":"73","author":"Rudek","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s11096-009-9323-y","article-title":"Paralytic ileus possibly associated with interaction between ritonavir\/lopinavir and vincristine","volume":"31","author":"Santucci","year":"2009","journal-title":"Pharm. World Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1470-2045(11)70056-0","article-title":"Use of antineoplastic agents in patients with cancer who have HIV\/AIDS","volume":"12","author":"Rudek","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200544020-00001","article-title":"Interactions between antiretrovirals and antineoplastic drug therapy","volume":"44","author":"Antoniou","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdr050","article-title":"Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression","volume":"23","author":"Antoniou","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/jamaoncol.2017.2844","article-title":"Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy","volume":"4","author":"Bryant","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/09540121.2018.1434120","article-title":"Mortality among people living with HIV\/AIDS with non-small-cell lung cancer in the modern HAART Era","volume":"30","author":"Smith","year":"2018","journal-title":"AIDS Care"},{"key":"ref_63","first-page":"111","article-title":"Lung cancer patients harboring epidermal growth factor receptor mutation among those infected by human immunodeficiency virus","volume":"8","author":"Okuma","year":"2015","journal-title":"Onco Targets. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1124\/dmd.113.052100","article-title":"Ritonavir and efavirenz significantly alter the metabolism of erlotinib\u2014An observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer","volume":"41","author":"Pillai","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3389\/fimmu.2019.01842","article-title":"Have Cells Harboring the HIV Reservoir Been Immunoedited?","volume":"10","author":"Huang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3389\/fimmu.2019.02109","article-title":"Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology","volume":"10","author":"Mylvaganam","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0169-5002(18)30036-9","article-title":"The influence of HIV status on programmed-death ligands expression in non-small cell lung cancer","volume":"115","author":"Kythreotou","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_73","first-page":"1","article-title":"Non-small cell lung cancer from HIV-infected patients expressed PD-L1 with marked inflammatory infiltrates","volume":"32","author":"Domblides","year":"2017","journal-title":"AIDS"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lungcan.2018.06.028","article-title":"Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection","volume":"123","author":"Scilla","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_75","first-page":"66","article-title":"B7-H3 role in the immune landscape of cancer","volume":"6","author":"Castellanos","year":"2017","journal-title":"Am. J. Clin. Exp. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00262-017-2103-y","article-title":"High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer","volume":"67","author":"Okuma","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005661","article-title":"Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection","volume":"12","author":"Hoffmann","year":"2016","journal-title":"PLoS Pathog."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/annonc\/mdy125","article-title":"Functional immune characterization of HIV-associated non-small-cell lung cancer","volume":"29","author":"Pinato","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Uldrick, T.S., Gon\u00e7alves, P.H., Abdul-Hay, M., Claeys, A.J., Emu, B., Ernstoff, M.S., Fling, S.P., Fong, L., Kaiser, J.C., and Lacroix, A.M. (2019). Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer\u2014A Phase 1 Study. JAMA Oncol.","DOI":"10.1001\/jamaoncol.2019.2244"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Bari, S., Chan, A., Jain, S.R., and Hostler, C.J. (2019). Outcomes of programmed cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) inhibitor therapy in HIV patients with advanced cancer. J. Oncol., 2019.","DOI":"10.1155\/2019\/7921582"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jtho.2018.03.031","article-title":"Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non\u2013Small Cell Lung Cancer","volume":"13","author":"Faig","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"E540","DOI":"10.21037\/jtd.2017.05.32","article-title":"Durable complete response to nivolumab in a patient with HIV and metastatic non-small cell lung cancer","volume":"9","author":"McCullar","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/annonc\/mdx696","article-title":"Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer","volume":"29","author":"Guihot","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S2352-3018(18)30295-9","article-title":"Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: A collaboration of cohort studies","volume":"6","author":"Althoff","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.trecan.2016.06.007","article-title":"Screening for Cancer in Persons Living with HIV Infection","volume":"2","author":"Goedert","year":"2016","journal-title":"Trends Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"National Lung Screening Trial Research Team, Aberle, D.R., Adams, A.M., Berg, C.D., Black, W.C., Clapp, J.D., Fagerstrom, R.M., Gareen, I.F., Gatsonis, C., and Marcus, P.M. (2011). Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N. Engl. J. Med., 365, 395\u2013409.","DOI":"10.1056\/NEJMoa1102873"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"National Lung Screening Trial Research Team, Church, T.R., Black, W.C., Aberle, D.R., Berg, C.D., Clingan, K.L., Duan, F., Fagerstrom, R.M., Gareen, I.F., and Gierada, D.S. (2013). Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer. N. Engl. J. Med., 368, 1980\u20131991.","DOI":"10.1056\/NEJMoa1209120"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/QAD.0000000000000943","article-title":"Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers","volume":"30","author":"Makinson","year":"2016","journal-title":"AIDS"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.21037\/jtd.2019.06.22","article-title":"HIV-infected patients with opportunistic pulmonary infections misdiagnosed as lung cancers: The clinicoradiologic features and initial application of CT radiomics","volume":"11","author":"Shi","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/COH.0000000000000321","article-title":"Cancer clinical trials in persons with HIV infection","volume":"12","author":"Little","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology\u2013Friends of Cancer Research HIV Working Group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1200\/JOP.2014.002709","article-title":"Cancer Treatment in Patients With HIV Infection and Non\u2013AIDS-Defining Cancers: A Survey of US Oncologists","volume":"11","author":"Suneja","year":"2015","journal-title":"J. Oncol. Pract."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/5\/1601\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:02:00Z","timestamp":1760173320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/5\/1601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":94,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["ijms21051601"],"URL":"https:\/\/doi.org\/10.3390\/ijms21051601","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,26]]}}}